Correvio Pharma Corp. announced the presentation of new data from the SPECTRUM study evaluating Brinavess (vernakalant hydrochloride, IV), the Company's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), in the emergency department setting at the American Heart Association (AHA) 2019 Annual Meeting taking place November 16-18, 2019, in Philadelphia. SPECTRUM was conducted as part of the follow-up measures agreed to with the European Medicines Agency in 2010 and enrolled 2,009 treatment episodes in 53 participating hospitals in the EU. Brinavess was administered in the emergency department in 64.2% of cases. In this post hoc analysis, 1,289 Brinavess treatment episodes in 1,120 unique patients in the emergency departments were assessed. The data demonstrated that treatment with Brinavess successfully converted 70.2% (95% confidence interval [CI] 67.5 - 72.7) of all treated episodes. Treatment with Brinavess also sho wed a median time to conversion of 12 minutes from start of first infusionamong patients who converted. The median length of stay was 7.5 hours in that setting. Only 13% of these emergency department patients remained in hospital for greater than 24 hours.